GSK Plc (GSK)
46.50
-0.04
(-0.09%)
USD |
NYSE |
Oct 09, 16:00
46.54
+0.04
(+0.09%)
After-Hours: 20:00
GSK Free Cash Flow (Quarterly) : 2.511B for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.511B |
| March 31, 2026 | 886.58M |
| December 31, 2025 | 1.396B |
| September 30, 2025 | 1.827B |
| June 30, 2025 | 1.632B |
| March 31, 2025 | 857.59M |
| December 31, 2024 | 1.329B |
| September 30, 2024 | 1.651B |
| June 30, 2024 | 554.48M |
| March 31, 2024 | 476.75M |
| December 31, 2023 | 2.676B |
| September 30, 2023 | 2.139B |
| June 30, 2023 | 665.87M |
| March 31, 2023 | -527.33M |
| December 31, 2022 | 886.96M |
| September 30, 2022 | 886.05M |
| June 30, 2022 | 1.015B |
| March 31, 2022 | 2.545B |
| December 31, 2021 | 3.986B |
| September 30, 2021 | 1.840B |
| June 30, 2021 | 573.38M |
| March 31, 2021 | -151.68M |
| December 31, 2020 | 3.509B |
| September 30, 2020 | 220.67M |
| June 30, 2020 | 2.488B |
| Date | Value |
|---|---|
| March 31, 2020 | 711.67M |
| December 31, 2019 | 2.929B |
| September 30, 2019 | 2.542B |
| June 30, 2019 | 567.66M |
| March 31, 2019 | 345.12M |
| December 31, 2018 | 4.271B |
| September 30, 2018 | 2.073B |
| June 30, 2018 | 1.020B |
| March 31, 2018 | 649.87M |
| December 31, 2017 | 2.383B |
| September 30, 2017 | 1.782B |
| June 30, 2017 | 161.50M |
| March 31, 2017 | 816.59M |
| December 31, 2016 | 2.518B |
| September 30, 2016 | 1.713B |
| June 30, 2016 | 771.03M |
| March 31, 2016 | -260.63M |
| December 31, 2015 | 808.48M |
| September 30, 2015 | -36.85M |
| June 30, 2015 | -692.85M |
| March 31, 2015 | -63.45M |
| December 31, 2014 | 2.207B |
| September 30, 2014 | 1.310B |
| June 30, 2014 | 254.04M |
| March 31, 2014 | 839.39M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| AstraZeneca PLC | 1.885B |
| Johnson & Johnson | 7.295B |
| Eli Lilly & Co. | 4.475B |
| Merck & Co., Inc. | 4.477B |
| Novo Nordisk A/S | 6.362B |